A Phase Ib Dose Finding Study Assessing Safety and Activity of [177Lu]Lu-DOTA-TATE in Newly Diagnosed Glioblastoma in Combination With Radiotherapy With or Without Temozolomide and in Recurrent Glioblastoma as Single Agent
Latest Information Update: 06 May 2024
At a glance
- Drugs Gallium 68-DOTATATE (Primary) ; Lutetium-(177Lu)-oxodotreotide (Primary) ; Temozolomide (Primary)
- Indications Glioblastoma
- Focus Adverse reactions
- Sponsors Novartis Pharmaceuticals
- 16 Nov 2023 Planned End Date changed from 2 Jun 2025 to 28 Jul 2026.
- 16 Nov 2023 Planned primary completion date changed from 31 May 2024 to 28 Jul 2025.
- 17 May 2023 Planned number of patients changed from 45 to 60.